0541 GMT - CSPC Pharmaceutical Group may benefit from higher success odds of its 'SYS6010' antibody-drug conjugate, China Galaxy International's Lily Wang says in a research report. SYS6010 has demonstrated tolerable safety and promising efficacy in both Epidermal Growth Factor Receptor-mutant and EGFR wild-type non-small cell lung cancer, the analyst notes. Also, management highlighted its business development performance in 2025 could exceed its previous guidance of 2-3 more deals, including at least three out-licensing deals worth over US$5 billion each, the analyst adds. The brokerage raises the stock's target price to HK$10.04 from HK$7.43 with an unchanged add rating. Shares are 6.2% lower at HK$7.60. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
June 02, 2025 01:41 ET (05:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.